工程益生菌分泌IL-18BP,并配备双单原子催化剂用于性结肠炎的协同治疗
Gongxi Qiao1, Shenglin Li1, Jianbin Liu1
1State Key Laboratory of Chemo/Bio-Sensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, P. R. China.
ACS applied materials & interfaces
|September 1, 2025
概括
这项研究引入了一种用于治疗性结肠炎 (UC) 的新生物平台. 这种工程化益生菌提供催化剂,减少氧化应激,调节炎症,恢复肠道微生物平衡,改善肠道平衡.
科学领域:
- 胃肠病学
- 纳米技术
- 微生物学
背景情况:
- 性结肠炎 (UC) 是由氧化应激和肠道失调引起的.
- 目前的治疗方法难以同时解决这些多方面的病理问题.
研究的目的:
- 开发一个综合性UC治疗的生物平台.
- 将双单原子催化剂 (DAC) 与工程益生菌结合起来,以增强治疗效果.
主要方法:
- 为了表达IL-18BP,改造了Nissle 1917 (EcN) 的大肠杆菌.
- 与工程 EcN 结合的 DAC 形成了 DEI 生物平台.
- 在酸诱导的大肠炎小鼠模型中口服DEI.
主要成果:
- DEI有效地清除了反应性氧物种 (ROS) 和中和了促炎细胞因子.
- 生物纳米平台增强了工程EcN殖民和治疗效果.
- 消化剂减轻了结肠炎症状,减少了炎症,恢复了肠道微生物的平衡.
结论:
- 多功能DEI生物平台为UC治疗提供了一个有希望的协同策略.
- 这种方法整合了ROS清理,免疫调节和微生物群恢复.
- 在临床前大肠炎模型中,生物纳米平台促进肠道平衡.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Inflammatory Bowel Disease IV: Pharmacological Management
185
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
185
Peptic Ulcer Disease IV: Management
145
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
145
Inflammatory Bowel Disease V: Surgical Management
206
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
206
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
264
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
264
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
595
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
595


